

# Eric Daugas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1079981/publications.pdf>

Version: 2024-02-01

105  
papers

11,212  
citations

66343

42  
h-index

29157

104  
g-index

115  
all docs

115  
docs citations

115  
times ranked

11807  
citing authors

#	ARTICLE	IF	CITATIONS
1	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. American Journal of Kidney Diseases, 2022, 79, 56-68.e1.	1.9	11
2	Mast cells in kidney regeneration. , 2022, , 103-126.		0
3	Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. Journal of the American Society of Nephrology: JASN, 2022, 33, 829-838.	6.1	23
4	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 1420-1427.	0.9	24
5	CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis. Nephrology Dialysis Transplantation, 2021, 36, 2256-2262.	0.7	5
6	Basophils and IgE contribute to mixed connective tissue disease development. Journal of Allergy and Clinical Immunology, 2021, 147, 1478-1489.e11.	2.9	14
7	Shiga Toxin-associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017. Emerging Infectious Diseases, 2021, 27, 1876-1885.	4.3	8
8	Arterial Thrombotic Events in Adult Inpatients With COVID-19. Mayo Clinic Proceedings, 2021, 96, 295-303.	3.0	49
9	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. Nephrology Dialysis Transplantation, 2021, 36, 1253-1262.	0.7	54
10	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine, 2021, 10, 1690.	2.4	10
11	Renal diseases secondary to interferon- $\gamma$ treatment: a multicentre clinico-pathological study and systematic literature review. CKJ: Clinical Kidney Journal, 2021, 14, 2563-2572.	2.9	8
12	Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. Journal of Nephrology, 2021, , 1.	2.0	2
13	Mast Cell Chymase and Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 302.	4.1	8
14	Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment. Kidney International, 2020, 97, 516-527.	5.2	14
15	SO058IGG4-RELATED KIDNEY DISEASE : A FRENCH NATIONWIDE RETROSPECTIVE COHORT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
16	COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. Journal of the American Society of Nephrology: JASN, 2020, 31, 2413-2423.	6.1	161
17	P0360URINARY PEPTIDOMIC ANALYSIS IN PROLIFERATIVE VERSUS NON-PROLIFERATIVE LUPUS NEPHRITIS : RESULTS OF THE PEPTIDU-LUP STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
18	Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy. Kidney International, 2020, 98, 241.	5.2	66

#	ARTICLE	IF	CITATIONS
19	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis) Tj ETQq1 1 0.784314 rgBT /Overloc	2.7	39
20	Basophil involvement in lupus nephritis: a basis for innovation in daily care. Nephrology Dialysis Transplantation, 2019, 34, 750-756.	0.7	5
21	Categorical state sequence analysis and regression tree to identify determinants of care trajectory in chronic disease: Example of end-stage renal disease. Statistical Methods in Medical Research, 2019, 28, 1731-1740.	1.5	13
22	Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. Kidney International, 2019, 96, 1020-1029.	5.2	32
23	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. Journal of Clinical Medicine, 2019, 8, 298.	2.4	3
24	Recruitment of CXCR3+ T cells into injured tissues in adult IgA vasculitis patients correlates with disease activity. Journal of Autoimmunity, 2019, 99, 73-80.	6.5	16
25	Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study. American Journal of Kidney Diseases, 2019, 73, 596-604.	1.9	24
26	Relative prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities in elderly haemodialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 848-858.	0.7	11
27	Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrology Dialysis Transplantation, 2019, 34, 1135-1144.	0.7	59
28	Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs. International Journal of Cardiology, 2019, 276, 208-211.	1.7	52
29	Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs. Nature Communications, 2018, 9, 725.	12.8	56
30	Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study. CKJ: Clinical Kidney Journal, 2018, 11, 73-79.	2.9	10
31	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. American Journal of Kidney Diseases, 2018, 72, 84-92.	1.9	94
32	Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. Journal of Autoimmunity, 2018, 89, 149-161.	6.5	48
33	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Annals of the Rheumatic Diseases, 2018, 77, 1150-1156.	0.9	139
34	Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients. CKJ: Clinical Kidney Journal, 2018, 11, 710-719.	2.9	7
35	Malakoplakia as a cause of severe hypercalcemia through ectopic 25-hydroxyvitamin D3 1-alpha-hydroxylase expression. Medicine (United States), 2018, 97, e12090.	1.0	5
36	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney International, 2018, 94, 1217-1226.	5.2	20

#	ARTICLE	IF	CITATIONS
37	FP592TWO-YEAR EVOLUTION OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS BACK TO DIALYSIS AFTER KIDNEY TRANSPLANT FAILURE.. Nephrology Dialysis Transplantation, 2018, 33, i241-i241.	0.7	0
38	IgA kappa light and heavy chain deposition disease in multiple myeloma. British Journal of Haematology, 2018, 183, 13-13.	2.5	0
39	Early Phase Mast Cell Activation Determines the Chronic Outcome of Renal Ischemiaâ€“Reperfusion Injury. Journal of Immunology, 2017, 198, 2374-2382.	0.8	30
40	Renal biopsies should be performed whenever treatment strategies depend on renal involvement. Annals of the Rheumatic Diseases, 2017, 76, e27-e27.	0.9	3
41	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90.	6.5	67
42	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
43	Metastatic Renal Cell Carcinoma in a Renal Allograft: A Sustained Complete Remission After Stimulated Rejection. American Journal of Transplantation, 2017, 17, 1125-1128.	4.7	3
44	SP333MANAGEMENT OF BONE AND MINERAL METABOLISM DISORDERS BEFORE THE DIALYSIS STAGE REMAINS STILL PERFECTIBLE DATA FROM THE FRENCH PHOSPHORUS AND CALCIUM SURVEY Â« PHOTO-GRAPHEÂ». Nephrology Dialysis Transplantation, 2017, 32, iii221-iii221.	0.7	0
45	Basophils contribute to pristane-induced Lupus-like nephritis model. Scientific Reports, 2017, 7, 7969.	3.3	28
46	Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nature Communications, 2017, 8, 246.	12.8	87
47	Serum Iron Protects from Renal Postischemic Injury. Journal of the American Society of Nephrology: JASN, 2017, 28, 3605-3615.	6.1	25
48	Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus. Medicine (United States), 2017, 96, e7429.	1.0	28
49	Rituximab alone as induction therapy for membranous lupus nephritis. Medicine (United States), 2017, 96, e7429.	1.0	28
50	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrology Dialysis Transplantation, 2017, 33, 1579-1590.	0.7	37
51	Facilitating access to the renal transplant waiting list does not increase the number of transplantations: comparative study of two French regions. CKJ: Clinical Kidney Journal, 2016, 9, 849-857.	2.9	7
52	Screening for vascular calcification in incident dialysis patients is not systematically performed. Nephrology Dialysis Transplantation, 2016, 31, 1369-1369.	0.7	1
53	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (United States), 2016, 95, e3748.	1.0	64
54	Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients. Kidney International, 2016, 89, 666-674.	5.2	36

#	ARTICLE	IF	CITATIONS
55	Protective role of mouse IgG1 in cryoglobulinaemia; insights from an animal model and relevance to human pathology. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1235-1242.	0.7	12
56	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. <i>PLoS ONE</i> , 2016, 11, e0151696.	2.5	13
57	Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e1243.	1.0	14
58	FP626LOW PARATHYROID HORMONE STATUS INDUCED BY HIGH DIALYSATE CALCIUM IS AN INDEPENDENT RISK FACTOR OF CARDIOVASCULAR DEATH IN HAEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii282-iii282.	0.7	0
59	Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002-2012. <i>Lupus</i> , 2015, 24, 1111-1121.	1.6	20
60	Brief Report: Childhood Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2015, 67, 1959-1965.	5.6	47
61	Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. <i>Kidney International</i> , 2015, 88, 276-285.	5.2	79
62	Mast cells in renal inflammation and fibrosis: Lessons learnt from animal studies. <i>Molecular Immunology</i> , 2015, 63, 86-93.	2.2	37
63	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1771-1780.	27.0	842
64	The Risk of Systemic Lupus Erythematosus Associated With Vaccines: An International Case-Control Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 1559-1567.	5.6	33
65	Immunoglobulin E plays an immunoregulatory role in lupus. <i>Journal of Experimental Medicine</i> , 2014, 211, 2159-2168.	8.5	78
66	Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2084-2091.	0.7	47
67	Autoreactive IgE Is Prevalent in Systemic Lupus Erythematosus and Is Associated with Increased Disease Activity and Nephritis. <i>PLoS ONE</i> , 2014, 9, e90424.	2.5	103
68	ANCA-associated diseases and lung carcinomas: a five-case series. <i>Clinical Nephrology</i> , 2014, 81, 132-137.	0.7	11
69	Mast cell chymase protects against renal fibrosis in murine unilateral ureteral obstruction. <i>Kidney International</i> , 2013, 84, 317-326.	5.2	38
70	Acute Renal Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 392-398.	4.5	135
71	Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. <i>Journal of Experimental Medicine</i> , 2012, 209, 793-806.	8.5	145
72	Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1114-1121.	0.7	46

#	ARTICLE	IF	CITATIONS
73	Mast Cells in Kidney Regeneration. , 2011, , 103-123.		0
74	Renal involvement in Castleman disease. Nephrology Dialysis Transplantation, 2011, 26, 599-609.	0.7	77
75	Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis. Journal of Rheumatology, 2011, 38, 2490-2490.	2.0	1
76	Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89â€“IgA and IgGâ€“IgA complexes: common mechanisms for distinct diseases. Kidney International, 2011, 80, 1352-1363.	5.2	69
77	Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nature Medicine, 2010, 16, 701-707.	30.7	287
78	Anti-angiogenic assay assists fetal extraction decision in a case of pre-eclampsia suspicion?. CKJ: Clinical Kidney Journal, 2010, 3, 427-428.	2.9	0
79	Mouse Mast Cell Protease-4 Deteriorates Renal Function by Contributing to Inflammation and Fibrosis in Immune Complex-Mediated Glomerulonephritis. Journal of Immunology, 2010, 185, 624-633.	0.8	64
80	Rituximab in Severe Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 579-587.	4.5	151
81	A Case Report of Adenovirus-Related Acute Interstitial Nephritis in a Patient With AIDS. American Journal of Kidney Diseases, 2008, 51, 121-126.	1.9	16
82	Acute Kidney Disease Due to Immune Reconstitution Inflammatory Syndrome in an HIV-Infected Patient With Tuberculosis. Journal of the International Association of Providers of AIDS Care, 2008, 7, 178-181.	1.2	26
83	Sodium Thiosulfate as First-Line Treatment for Calciphylaxis. Archives of Dermatology, 2007, 143, 1336-7; author reply 1338.	1.4	39
84	Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological Considerations. American Journal of Kidney Diseases, 2007, 49, 158-161.	1.9	93
85	Immuno-allergic interstitial nephritis related to fluindione: first biopsy proven cases. Nephrology Dialysis Transplantation, 2006, 21, 237-237.	0.7	6
86	Renal Cortical Necrosis Related to Paraneoplastic Antiphospholipid Syndrome. American Journal of Kidney Diseases, 2006, 47, 1072-1074.	1.9	6
87	Acute renal failure associated with immune restoration inflammatory syndrome. Nature Clinical Practice Nephrology, 2006, 2, 594-598.	2.0	21
88	HAART-related nephropathies in HIV-infected patients. Kidney International, 2005, 67, 393-403.	5.2	104
89	AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene, 2004, 23, 1514-1521.	5.9	254
90	Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene, 2003, 22, 6669-6678.	5.9	251

#	ARTICLE	IF	CITATIONS
91	Platelet formation is the consequence of caspase activation within megakaryocytes. <i>Blood</i> , 2002, 100, 1310-1317.	1.4	308
92	Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. <i>Biochimie</i> , 2002, 84, 215-222.	2.6	472
93	Wild-type p53 induced sensitization of mutant p53 TNF-resistant cells: Role of caspase-8 and mitochondria. <i>Cancer Gene Therapy</i> , 2002, 9, 219-227.	4.6	23
94	DNA binding is required for the apoptogenic action of apoptosis inducing factor. <i>Nature Structural Biology</i> , 2002, 9, 680-684.	9.7	319
95	Heat-shock protein 70 antagonizes apoptosis-inducing factor. <i>Nature Cell Biology</i> , 2001, 3, 839-843.	10.3	790
96	Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. <i>Nature</i> , 2001, 410, 549-554.	27.8	1,212
97	Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. <i>FASEB Journal</i> , 2001, 15, 758-767.	0.5	226
98	Mitochondrial nuclear translocation of AIF in apoptosis and necrosis. <i>FASEB Journal</i> , 2000, 14, 729-739.	0.5	723
99	Two Distinct Pathways Leading to Nuclear Apoptosis. <i>Journal of Experimental Medicine</i> , 2000, 192, 571-580.	8.5	665
100	The HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore. <i>Journal of Experimental Medicine</i> , 2000, 191, 33-46.	8.5	428
101	Kidney Involvement in the Antiphospholipid Syndrome. <i>Journal of Autoimmunity</i> , 2000, 15, 127-132.	6.5	15
102	Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. <i>FEBS Letters</i> , 2000, 476, 118-123.	2.8	390
103	The Intrarenal Vascular Lesions Associated with Primary Antiphospholipid Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 507-518.	6.1	259
104	The Central Executioner of Apoptosis: Multiple Connections between Protease Activation and Mitochondria in Fas/APO-1/CD95- and Ceramide-induced Apoptosis. <i>Journal of Experimental Medicine</i> , 1997, 186, 25-37.	8.5	615
105	CT-M8 Mice: A New Mouse Model Demonstrates That Basophils Have a Nonredundant Role in Lupus-Like Disease Development. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5